Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Trifecta Study: Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

NCT03823131 is registered in ClinicalTrials.gov with Chase Heaton, MD as lead sponsor.

NCT NCT03823131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03823131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Trifecta Study: Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
Lead sponsor
Chase Heaton, MD
Phase
Phase 2
Overall status
Terminated
Start date
May 2, 2019
Completion date
July 31, 2022
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic head and neck squamous cell carcinoma, recurrent head and neck squamous cell carcinoma, unresectable head and neck squamous cell carcinoma